ClinicalTrials.gg
CompletedNCT00648999Updated Mar 15, 2013

Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients

A Phase 4 interventional study of lopinavir/ritonavir in Human Immunodeficiency Virus, sponsored by AbbVie (prior sponsor, Abbott). Completed at 13 sites in Mexico. Open to participants aged 17 Years and older. Per ClinicalTrials.gov, last updated 2013-03-15.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
207
Allocation
Non-randomized
Ages
17 Years and older
Sex
All
01

Study summary

To demonstrate that patients treated with Kaletra have an improvement in their quality of life compared to the quality of life they had with their previous NRTI therapy.

02

Conditions studied

  • Human Immunodeficiency Virus

Browse trials for

Keywords

  • Kaletra
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 207 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
17 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infected subjects
  • Subjects failing in current HIV treatment, or
  • Subjects with a viral load \< 400 copies/mL and not tolerating their current HIV treatment.

Exclusion criteria

Exclusion Criteria:

  • Subject is currently participating in another clinical study or has participated in another clinical study within 30 days prior to screening visit
  • Subject is pregnant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
207 participants (actual)

Study arms

  • Active comparator
    1

    Drug: lopinavir/ritonavir

  • Active comparator
    2

    Drug: lopinavir/ritonavir

Interventions

  • Druglopinavir/ritonavir

    lopinavir/ritonavir 400 mg/100 mg bid 48 weeks of treatment

    Also known as: ABT-378, Kaletra

06

What researchers measure

Primary outcomes

  1. Quality of Life

    Time frame: Baseline, Week 4, Week 24 and Week 48

  2. CD4

    Time frame: Baseline, Week 24 and Week 48

Secondary outcomes

  1. Adverse Event Monitoring

    Time frame: Baseline, Week 4, Week 24 and Week 48

07

Study locations

13 sites
  • Site Ref # / Investigator 4049
    Mexico City, Distrito Federal 01030, Mexico
  • Site Ref # / Investigator 4050
    Mexico City, Distrito Federal 01120, Mexico
  • Site Ref # / Investigator 4051
    Mexico City, Distrito Federal 09220, Mexico
  • Site Ref # / Investigator 4077
    Mexico City, Distrito Federal 10300, Mexico
  • Site Ref # / Investigator 4056
    Mexico City, Distrito Federal, Mexico
  • Site Ref # / Investigator 4074
    Leon, Guanajauto, Mexico
  • Site Ref # / Investigator 4054
    Morelia, Michoacan, Mexico
  • Site Ref # / Investigator 4072
    Tepic, Nayarit, Mexico
  • Site Ref # / Investigator 4055
    Culiacan, Sinaloa, Mexico
  • Site Ref # / Investigator 4075
    Merida, Yucatan 97219, Mexico
  • Site Ref # / Investigator 4073
    Chihuahua, 31310, Mexico
  • Site Ref # / Investigator 4052
    Oaxaca, Mexico
  • Site Ref # / Investigator 4053
    Puebla, 72570, Mexico
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2003, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2008
First posted
Apr 1, 2008
Start
Nov 2003
Primary completionActual
Dec 2006
CompletionActual
Dec 2006
Last update
Mar 15, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00648999
Responsible party
Sponsor
First posted
Apr 1, 2008
Start date
Nov 2003
Primary completion
Dec 2006
Completion
Dec 2006
Last update
Mar 15, 2013

Study contacts

Jose Canadas, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion